靶向SIRT1激活营养感知提升老年人内在能力的研究进展

doi:10.3969/j.issn.1003-9198.2026.10.013

摘要/Abstract

摘要： 内在能力(intrinsic capacity, IC)是指个体在任何时候能动用的体力和脑力的总和,涵盖认知、运动、感觉、心理和活力五个维度。IC下降是不良健康结局的重要预测指标。针对老年人IC衰退的病理机制研究仍处于起步阶段,延缓老年人IC衰退的靶向治疗策略尚缺乏。去乙酰化酶 1(SIRT1)作为体内营养感知通路的核心调控因子,其活性随烟酰胺腺嘌呤二核苷酸(NAD⁺)水平下降而降低,与衰弱、肌少症、认知减退、营养不良、抑郁等多种衰老相关性疾病的发生关系密切,是IC衰退的重要病理基础。本综述首次系统整合SIRT1调控网络引起IC衰退的分子证据,探索靶向SIRT1激活提升老年人IC的治疗潜力与临床转化价值。

关键词: 衰老, 内在能力, 营养感知失调, 去乙酰化酶1, 干预策略

Abstract: Intrinsic capacity refers to the composite of physical and mental capacities of an individual, including five domains: cognition, locomotion, sensory capacity, psychology, and vitality. Decline in intrinsic capacity is an important predictor of adverse health outcomes. However, the mechanisms underlying intrinsic capacity decline remain incompletely defined, and targeted therapeutic strategies are still lacking. Sirtuin 1(SIRT1), a core regulator of nutrient-sensing pathways, exhibits reduced activity during aging. The dysregulation of SIRT1 has been linked to a variety of age-related diseases, including frailty, sarcopenia, cognitive decline, malnutrition, and depression, highlighting its critical function in intrinsic capacity decline. This review aims to outline the current molecular evidence on SIRT1 dysregulation in the onset and progression of intrinsic capacity decline, and to explore novel intervention strategies for enhancing intrinsic capacity through SIRT1 activation.

Key words: aging, intrinsic capacity, deregulated nutrient-sensing, Sirtuin 1, intervention strategy

中图分类号:

R592

朱欢, 王双, 孙倩倩. 靶向SIRT1激活营养感知提升老年人内在能力的研究进展[J]. 实用老年医学, 2026, 40(10): 1043-1047.

ZHU Huan, WANG Shuang, SUN Qianqian. Research progress in targeting SIRT1 dependent nutrient sensing for enhancing the intrinsic capacity of older adults[J]. Practical Geriatrics, 2026, 40(10): 1043-1047.

参考文献

[1] BEARD J R, OFFICER A, DE CARVALHO I A, et al. The world report on ageing and health: a policy framework for healthy ageing[J]. Lancet, 2016, 387(10033): 2145-2154.
[2] QIANG L, LIN H V, KIM-MULLER J Y, et al. Proatherogenic abnormalities of lipid metabolism in SIRT1 transgenic mice are mediated through Creb deacetylation[J]. Cell Metab, 2011, 14(6): 758-767.
[3] PARMAR U M, JALGAONKAR M P, KULKARNI Y A, et al. Autophagy-nutrient sensing pathways in diabetic complications[J]. Pharmacol Res, 2022, 184: 106408.
[4] ZHOU S, TANG X, CHEN H Z. Sirtuins and insulin resistance[J]. Front Endocrinol, 2018, 9: 748.
[5] BAUTMANS I, KNOOP V, AMUTHAVALLI THIYAGARAJAN J, et al. WHO working definition of vitality capacity for healthy longevity monitoring[J]. Lancet Healthy Longev, 2022, 3(11): e789-e796.
[6] FERRUCCI L, FABBRI E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty[J]. Nat Rev Cardiol, 2018, 15(9): 505-522.
[7] SUN H, LI D, WEI C, The relationship between SIRT1 and inflammation: a systematic review and meta-analysis[J]. Front Immunol, 2024, 15: 1465849.
[8] XU H, ZENG S, WANG Y, et al. Cytoplasmic SIRT1 promotes paclitaxel resistance in ovarian carcinoma through increased formation and survival of polyploid giant cancer cells[J]. J Pathol, 2023, 261(2): 210-226.
[9] XIE J, CHE S, LIU J, et al. SIRT1: potential target in glucocorticoid-resistant diseases[J]. Front Immunol, 2025, 16: 1514745.
[10] YANG L, LIU D, JIANG S, et al. SIRT1 signaling pathways in sarcopenia: novel mechanisms and potential therapeutic targets[J]. Biomed Pharmacother, 2024, 177: 116917.
[11] BRAULT J J, JESPERSEN J G, GOLDBERG A L. Peroxisome proliferator-activated receptor gamma coactivator 1alpha or 1beta overexpression inhibits muscle protein degradation, induction of ubiquitin ligases, and disuse atrophy[J]. J Biol Chem, 2010, 285(25): 19460-19471.
[12] THOMA A, LIGHTFOOT A P. NF-κB and inflammatory cytokine signalling: role in skeletal muscle atrophy[J]. Adv Exp Med Biol, 2018, 1088: 267-279.
[13] MIGLIAVACCA E, TAY S K H, PATEL H P, et al. Mitochondrial oxidative capacity and NAD(+) biosynthesis are reduced in human sarcopenia across ethnicities[J]. Nat Commun, 2019, 10(1): 5808.
[14] CHUBANAVA S, KARAVAEVA I, EHRLICH A M, et al. NAD depletion in skeletal muscle does not compromise muscle function or accelerate aging[J]. Cell Metab, 2025, 37(7): 1460-1481.e17.
[15] CAO K, DONG Y T, XIANG J, et al. Reduced expression of SIRT1 and SOD-1 and the correlation between these levels in various regions of the brains of patients with Alzheimer’s disease[J]. J Clin Pathol, 2018, 71(12): 1090-1099.
[16] BENUSSI A, VUCIC S. Emergent technologies and applications of TMS and TMS-EEG in clinical neurophysiology for early and differential diagnosis: IFCN handbook chapter[J]. Clin Neurophysiol, 2026, 182: 2111459.
[17] XUE S, WANG J, TIAN Y, et al. Hemorrhagic shock and reperfusion induced cognitive impairment through HIF3α/SIRT1[J]. Free Radic Biol Med, 2025, 240: 491-503.
[18] WU W F, CHEN C, LIN J T, et al. Impaired synaptic plasticity and decreased glutamatergic neuron excitability induced by SIRT1/BDNF downregulation in the hippocampal CA1 region are involved in postoperative cognitive dysfunction[J]. Cell Mol Biol Lett, 2024, 29(1): 79.
[19] BAI N, LIU S, WEI J, et al. Sirtuins in Alzheimer’s disease: mechanistic insights and therapeutic opportunities[J]. Trends Pharmacol Sci, 2026, 47(1): 100-119.
[20] KUJAWOWICZ K, MIROŃCZUK-CHODAKOWSKA I, WITKOWSKA A M. Sirtuin 1 as a potential biomarker of undernutrition in the elderly: a narrative review[J]. Crit Rev Food Sci Nutr, 2024, 64(26): 9532-9553.
[21] LING C, VERSLOOT C J, ARVIDSSON KVISSBERG M E, et al. Rebalancing of mitochondrial homeostasis through an NAD(+)-SIRT1 pathway preserves intestinal barrier function in severe malnutrition[J]. EBioMedicine, 2023, 96: 104809.
[22] LUO Y L, WU H Y, MIN X, et al. SIRT1 prevents noise-induced hearing loss by enhancing cochlear mitochondrial function[J]. Cell Commun Signal, 2025, 23(1): 160.
[23] ZENG C, LIN W, GU X, et al. Metformin alleviates presbycusis by activating the SIRT1/PINK1/GPX4 pathway in vitro and in vivo[J]. Inflammopharmacology, 2026, 34: 729-741.
[24] MOSHTAGHION S M, CABALLANO-INFANTES E, PLAZA REYES Á, et al. Piceid octanoate protects retinal cells against oxidative damage by regulating the sirtuin 1/poly-ADP-ribose polymerase 1 axis in vitro and in rd10 mice[J]. Antioxidants: Basel, 2024, 13(2): 201.
[25] HAMMER S S, VIEIRA C P, MCFARLAND D, et al. Fasting and fasting-mimicking treatment activate SIRT1/LXRα and alleviate diabetes-induced systemic and microvascular dysfunction[J]. Diabetologia, 2021, 64(7): 1674-1689.
[26] ABE-HIGUCHI N, UCHIDA S, YAMAGATA H, et al. Hippocampal sirtuin 1 signaling mediates depression-like behavior[J]. Biol Psychiatry, 2016, 80(11): 815-826.
[27] LEI Y, WANG J, WANG D, et al. SIRT1 in forebrain excitatory neurons produces sexually dimorphic effects on depression-related behaviors and modulates neuronal excitability and synaptic transmission in the medial prefrontal cortex[J]. Mol Psychiatry, 2020, 25(5): 1094-1111.
[28] XU L, CAO Y, ZHANG S, et al. Sirtuin 1 underlies depression-related behaviors by modulating the serotonin system in the dorsal raphe nucleus in female mice[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2025, 139: 111400.
[29] KIM H D, HESTERMAN J, CALL T, et al. SIRT1 mediates depression-like behaviors in the nucleus accumbens[J]. J Neurosci, 2016, 36(32): 8441-8452.
[30] ALWAY S E, MCCRORY J L, KEARCHER K, et al. Resveratrol enhances exercise-induced cellular and functional adaptations of skeletal muscle in older men and women[J]. J Gerontol A Biol Sci Med Sci, 2017, 72(12): 1595-1606.
[31] CHEN Y C, CHOU M Y, LI P H, et al. New insights into potential anti-aging and fatigue effects of a dietary supplement from the resveratrol beverage in aged SAMP8 mice[J]. Antioxidants: Basel, 2025, 14(11): 1337.
[32] WITTE A V, KERTI L, MARGULIES D S, et al. Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults[J]. J Neurosci, 2014, 34(23): 7862-7870.
[33] BIJU B K, ANDAVAR M. Resveratrol: potential therapeutic effects on ocular health[J]. Inflammopharmacology, 2025, 33(10): 5757-5768.
[34] THIYAGARAJAN R, MUTHAIAH R, SREEVELU B, et al. Nicotinamide riboside supplementation restores microglial health and improves cognition in aged male mice[J]. Geroscience, 2025: 1-24.
[35] PROKOPIDIS K, MORIARTY F, BAHAT G, et al. The effect of nicotinamide mononucleotide and riboside on skeletal muscle mass and function: a systematic review and meta-analysis[J]. J Cachexia Sarcopenia Muscle, 2025, 16(3): e13799.
[36] KETRON G L, GRUN F, GRILL J D, et al. Pharmacokinetic and pharmacodynamic assessment of oral nicotinamide in the NEAT clinical trial for early Alzheimer’s disease[J]. Alzheimers Res Ther, 2025, 17(1): 59.
[37] VREONES M, MUSTAPIC M, MOADDEL R, et al. Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin[J]. Aging Cell, 2023, 22(1): e13754.
[38] ORR M E, AL E. A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment[J]. GeroScience, 2024, 46(1): 665-682.
[39] ANWAR M, PRADHAN R, DEY S, et al. The role of sirtuins in sarcopenia and frailty[J]. Aging Dis, 2023, 14(1): 25-32.
[40] ARMAMENTO-VILLAREAL R, AGUIRRE L, WATERS D L, et al. Effect of aerobic or resistance exercise, or both, on bone mineral density and bone metabolism in obese older adults while dieting: a randomized controlled trial[J]. J Bone Miner Res, 2020, 35(3): 430-439.